Block admission six monthly return
In brief · summary, not quotable
No summary for this filing – the full text is below.
Full announcement
Select text to share a quote on X · sign in to keep highlights & notes in your FAB notes
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces the following information in connection with its block admission pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies.
| Name of company: | Fusion Antibodies plc |
| Name of scheme: | Historic options, EMI and Unapproved Employee Share Option Scheme, as announced on 27 September 2021 |
| Period of return: | From 2 October 2023 to 1 April 2024 |
| Number and class of securities not issued under the scheme at the beginning of the period: | 293,750 ordinary shares of 4 pence each in the Company ("Ordinary Shares") |
| Number of securities issued under the scheme during the period: | Nil |
| Number of options under the scheme that have lapsed during the period: | Options over 255,000 Ordinary Shares |
| Balance under the scheme of securities not yet issued at the end of the period: | 38,750 Ordinary Shares |
| Number and class of securities originally admitted and the date of admission: | 917,083 Ordinary Shares on 27 September 2021 |
| Contact name and telephone number: | Stephen Smyth, Interim CFO via Walbrook PR +44 (0)20 7933 8780 |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.